Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Could a vaccine help fight food allergies?

A dramatic rise in food allergies over the past 20 years had Australian medical professionals scratching their heads, with three in every ten babies born each year developing food-related allergy or eczema.

Horse wisdom making a difference in the Kimberley

The Yawardani Jan-ga Equine-Assisted Learning (EAL) research project, headed by Professor Juli Coffin in WA’s Kimberley region, is steadily growing its capacity to support the social, emotional and spiritual wellbeing of Aboriginal young people through the powerful medium of horses.

Cerebral Palsy Respiratory Health

We know from research that the risk of death from respiratory disease is 14 times higher for adults with cerebral palsy than for other adults. Respiratory disease is the most common cause of premature death in children and young people with cerebral palsy and one of the main causes of hospitalisation.

Questions about vaccines

The Kids Research Institute Australia answers all of your questions about vaccines and children

Research

Measles

Measles is a highly contagious infectious disease that can cause severe, long-term complications in children.

Research

Respiratory Syncytial Virus (RSV)

RSV hospitalises millions of babies worldwide every year: our research is helping to change that.

Research

Prostaglandin E2 imprints a long-lasting effect on dendritic cell progenitors in the bone marrow

Injection of BM-differentiated DCs from nonchimeric mice restored the reduced immune responses of PGE2-chimeric mice.

Research

In utero exposure to low dose arsenic via drinking water impairs early life lung mechanics in mice

All alterations to lung mechanics following in utero arsenic exposure were recovered by adulthood.

Research

Parental smoking and risk of childhood brain tumors

Childhood brain tumors (CBT) are the leading cause of cancer death in children, yet their etiology remains largely unknown.

Research

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

No currently licensed and available vaccine has been shown to provide broad protection against endemic MnB disease.